Search

Despite the promising clinical benefits of therapies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) with antibodies in various cancers, resistance to these therapies will inevitably develop following treatment. Recent studies suggest that crosstalk between the EGFR and VEGF signaling pathways might be involved in the development of resistance. Therefore, simultaneous blockade of EGFR and VEGF signaling may be able to counteract this resistance and improve clinical outcomes. Here, we devised a fusion protein with two copies of VEGFR1 domain 2 connected to the C-terminus of cetuximab that can simultaneously bind to EGFR and VEGF and effectively inhibit target cell growth mediated by these two pathways. Furthermore, the fusion protein could bring soluble VEGF into target cells for degradation through internalization upon binding to EGFR. Tissue distribution in mice confirmed that the fusion protein effectively accumulated in tumors compared to its mAb counterpart cetuximab. These features resulted in stronger antitumor efficacies in vivo than the combination of bevacizumab and cetuximab. Thus, we provide a promising new strategy for the treatment of EGFR-overexpressing cancers.

Targeting PD1/PDL1 with blocking antibodies for cancer therapy has shown promising benefits in the clinic, but only approximately 20–30% of patients develop durable clinical responses to the treatment. Bispecific antibodies (BsAbs) that combine PD1/PDL1 blockade with the modulation of another immune checkpoint target may have greater potential to enhance immune checkpoint blockade therapy. In this study, we identified an anti-PD1 monoclonal antibody, 609A, whose heavy chain can pair with a variety of light chains from different antibodies while maintaining its PD1 binding/blocking activity. Taking advantage of this property and using a linear F(ab’)2 format, we successfully produced a series of tetravalent IgG-like BsAbs that simultaneously target PD1 and other immune checkpoint targets, including PDL1 and CTLA4. The BsAbs exhibited superior bioactivities in vitro and in vivo compared to their respective parental mAbs. Importantly, the BsAbs demonstrated the desired IgG-like physicochemical properties in terms of high-level expression, ease of purification to homogeneity, good stability and in vivo pharmacokinetics. In summary, we describe a novel and flexible plug-and-play platform to engineer IgG-like BsAbs with excellent development potential for clinical applications.

We developed a strategy to combine conventional targeted therapy with immune checkpoint blockade using a tumor-targeting bispecific antibody (BsAb) to treat solid tumors. The BsAb was designed to simultaneously engage a tumor-associated antigen, epidermal growth factor receptor (EGFR), and programed cell death protein 1 (PD1). In addition to its direct anti-tumor activity via EGFR inhibition, the BsAb mediated efficient antibody-dependent cellular cytotoxicity (ADCC) and activated T cell antitumor im munity through blockade of PD1 from interacting with its counterpart, programed cell death ligand 1 (PDL1). Further, the BsAb exhibited a potent direct tumor cell killing activity in the presence of PBMC, most likely, via activating and, at the same time, physically engaging T cells with tumor cells. Taken together, we here illustrate a new strategy in the design and production of novel BsAbs with enhanced therapeutic efficacy through both direct tumor growth inhibition and T cell activation via tumor-targeted immune checkpoint blockade.

Platelet-derived growth factor receptor β (PDGFRβ) is upregulated in most of solid tumors. It is expressed by pericytes/smooth muscle cells, fibroblast, macrophage, and certain tumor cells. Several PDGF receptor-related antagonists are being developed as potential antitumor agents and have demonstrated promising antitumor activity in both preclinical and clinical settings. Here, we produced a fully human neutralizing antibody, IMC-2C5, directed against PDGFRβ from an antibody phage display library. IMC-2C5 binds to both human and mouse PDGFRβ and blocks PDGF-B from binding to the receptor. IMC-2C5 also blocks ligand-stimulated activation of PDGFRβ and downstream signaling molecules in tumor cells. In animal studies, IMC-2C5 significantly delayed the growth of OVCAR-8 and NCI-H460 human tumor xenografts in nude mice but failed to show antitumor activities in OVCAR-5 and Caki-1 xenografts. Our results indicate that the antitumor efficacy of IMC-2C5 is primarily due to its effects on tumor stroma, rather than on tumor cells directly. Combination of IMC-2C5 and DC101, an anti-mouse vascular endothelial growth factor receptor 2 antibody, resulted in significantly enhanced antitumor activity in BxPC-3, NCI-H460, and HCT-116 xenografts, compared with DC101 alone, and the trend of additive effects to DC101 treatment in several other tumor models. ELISA analysis of NCI-H460 tumor homogenates showed that IMC-2C5 attenuated protein level of vascular endothelial growth factor and basic fibroblast growth factor elevated by DC101 treatment. Finally, IMC-2C5 showed a trend of additive effects when combined with DC101/chemotherapy in MIA-PaCa-2 and NCI-H460 models. Taken together, these results lend great support to the use of PDGFRβ antagonists in combination with other antiangiogenic agents in the treatment of a broad range of human cancers.

Accumulating evidence suggests that multiple complex mechanisms may be involved, simultaneously or complementarily, in the emergence and development of multidrug resistance (MDR) in various cancers. Cell adhesion-mediated MDR is one such mechanism. In the present study, we initially observed increased cell adhesion to extracellular matrix proteins by the MDR human breast tumor cell line MCF-7/MX compared to its parental cells. We then used a strategy that combined antibody-based screening technique and mass spectrometry-based proteomics to identify membrane proteins that contribute to the enhanced adhesion of MCF-7/MX cells. Using MCF-7/MX cells as immunogen, we isolated a mouse monoclonal antibody, 9C6, that preferentially reacts with MCF-7/MX cells over the parental MCF-7 cells. The molecular target of 9C6 was identified as cytokeratin 8 (CK8), which was found to be overexpressed on the cell surface of MCF-7/MX cells. We further observed that down-regulation of cell surface levels of CK8 through siRNA transfection significantly inhibited MCF-7/MX cell adhesion to fibronectin and vitronectin. In addition, anti-CK8 siRNA partially reversed the MDR phenotype of MCF-7/MX cells. Taken together, our results suggest that alterations in the expression level and cellular localization of CK8 may play a significant role in enhancing the cellular adhesion of MDR MCF-7/MX cells.

The morphologies and structures of carbon nanotubes and the related byproducts and intermediates produced by floating chemical vapor deposition (CVD) and denotation-assisted CVD processes are studied. The function of metals is to promote the anisotropic interactions between the nanoparticles and the structural crystallization.

A self-catalysis behavior of multi-walled carbon nanotubes is proposed and is experimentally validated under the conditions in which only metal catalysis was figured to work. The self-catalysis could support the nucleation and radical and axial developing processes.

Fe/N/C catalysts are proven to be highly active for oxygen reduction reaction (ORR). The detailed kinetic and thermodynamic ORR behavior on FeN3-G (three-coordinated FeN3 center embedded in graphene) based on density functional theory is investigated in this work. The results show that O2 dissociation mechanism with a high active barrier is unfavorable. All ORR intermediates except H2O2 can be chemisorbed stably on the surface. H2O2 is easily dissociated, which indicates that a two-electron pathway is impossible. This conclusion is further supported by the calculations of OOH dissociation reaction barriers, which are extremely low. The results prove that FeNj-G catalysts promote four-electron ORR. Given the high adsorption energy of the surface toward O2, the O2(ads)-to-OOH(ads) reaction has the highest reaction barrier in the whole reduction steps, which functions as the kinetic rate-determining step. However, free energy diagrams show that reduction of OH into H2O remains uphill for all positive electrode potential vs. the normal hydrogen electrode. The high endothermic AG value of H2O formation indicates this step is the most sluggish one and implies the highest resistance for the whole ORR. The FeN3-G is not a well catalyst for ORR. [ABSTRACT FROM AUTHOR]

Primary alkyl alcohols can be directly converted into acetals and H2 via TiO2-photocatalytic dehydrogenation coupling at room temperature, with no need for any hydrogen acceptors. The reaction follows a tandem process integrating photocatalytic alcohol dehydrogenation and H+ -catalytic acetalation, in which the H+ ion catalysts are provided by the alcohol dehydrogenation in real time. This approach exhibits a very high reaction rate and product selectivity, and represents a novel green process for the conversion of primary alkyl alcohols, especially for bio-renewable ethanol and 1-butanol. [ABSTRACT FROM AUTHOR]

Modulation of the TiO[sub 2] structure to achieve efficient photocatalytic usage of solar light is still a challenging issue. Here we report that simple bombardment of anatase TiO[sub 2] nanocrystals by hot molecules can alter its phase transformation kinetics and lead to the reconstruction of the resulting rutile surfaces into a metastable TiO[sub 2] crystalline structure. Moreover, the metastable surface crystalline phase is able to harvest visible light up to 480 nm, and exhibits good properties for photocurrent generation. Photocatalysis tests show that upon irradiation by visible light (λ > 420 nm), the surface-reconstructed TiO[sub 2] crystals display excellent and stable photocatalytic activity for hydrogen production from aqueous ethanol solution, with a hydrogen production rate of 302 µmol g[sup -1] h[sup -1]. This finding might bring a new approach to kinetically tune the structure of TiO[sub 2] or other semiconductor crystals in order to modulate their properties. [ABSTRACT FROM AUTHOR]

AbstractMonoclonal antibodies (mAb) are emerging as one of the major class of therapeutic agents in the treatment of many human diseases, in particular in cancer and immunological disorders. To date, 28 mAb have been approved by the United States Food and Drug Administration for clinical applications. In addition, several hundreds of mAb are being developed clinically by many biotech and pharmaceutical companies for various disease indications. Many challenges still remain, however, and the full potential of therapeutic antibodies has yet to be realized. With the advancement of antibody engineering technologies and our further understanding of disease biology as well as antibody mechanism of action, many classes of novel antibody formats or antibody derived molecules are emerging as promising new generation therapeutics. These new antibody formats or molecules are carefully designed and engineered to acquire special features, such as improved pharmacokinetics, increased selectivity, and enhanced efficacy. These new agents may have the potential to revolutionize both our thinking and practice in the efforts to research and develop next generation antibody-based therapeutics. [ABSTRACT FROM AUTHOR]

Disregulated Wnt/β-catenin signaling has been linked to various human diseases, including cancers. Inhibitors of oncogenic Wnt signaling are likely to have a therapeutic effect in cancers. LRP5 and LRP6 are closely related membrane coreceptors for Wnt proteins. Using a phage-display library, we identified anti-LRP6 antibodies that either inhibit or enhance Wnt signaling. Two classes of LRP6 antagonistic antibodies were discovered: one class specifically inhibits Wnt proteins represented by Wnt1, whereas the second class specifically inhibits Wnt proteins represented by Wnt3a. Epitope-mapping experiments indicated that Wnt1 class-specific antibodies bind to the first propeller and Wnt3a class-specific antibodies bind to the third propeller of LRP6, suggesting that Wnt1- and Wnt3a-class proteins interact with distinct LRP6 propeller domains. This conclusion is further supported by the structural functional analysis of LRP5/6 and the finding that the Wnt antagonist Sclerostin interacts with the first propeller of LRP5/6 and preferentially inhibits the Wnt1-class proteins. We also show that Wnt1 or Wnt3a class-specific anti-LRP6 antibodies specifically block growth of MMTV-Wnt1 or MMTV-Wnt3 xenografts in vivo. Therapeutic application of these antibodies could be limited without knowing the type of Wnt proteins expressed in cancers. This is further complicated by our finding that bivalent LRP6 antibodies sensitize cells to the nonblocked class of Wnt proteins. The generation of a biparatopic LRP6 antibody blocks both Wnt1- and Wnt3a-mediated signaling without showing agonistic activity. Our studies provide insights into Wnt-induced LRP5/6 activation and show the potential utility of LRP6 antibodies in Wnt-driven cancer. [ABSTRACT FROM AUTHOR]

VEGF coordinates complex regulation of cellular regeneration and interactions between endothelial and perivascular cells; dysfunction of the VEGF signaling system leads to retinopathy. Here, we show that systemic delivery of VEGF and placental growth factor (PIGF) by protein implantation, tumors, and adenoviral vectors ablates pericytes from the mature retinal vasculature through the VEGF receptor 1 (VEGFR1)-mediated signaling pathway, leading to increased vascular leakage. In contrast, we demonstrate VEGF receptor 2 (VEGFR2) is primarily expressed in nonvascular photo-receptors and ganglion cells. Moreover, blockade of VEGFR1 but not VEGFR2 significantly restores pericyte saturation in mature retinal vessels. Our findings link VEGF and PIGF to cancer-associated retinopathy, reveal the molecular mechanisms of VEGFR1 ligandmediated retinopathy, and define VEGFR1 as an important target of antiangiogenic therapy for treatment of retinopathy. [ABSTRACT FROM AUTHOR]

Multi-wall carbon nanotubes can readily form by the catalysis of lanthanide oxides. The formed tubes are unusually separated from the catalyst particles, which leads to a straightforward identification of the self-assembly of carbon particles that is hidden in the chaotic carbon-catalyst-hybrid system of catalytic carbon nanotube evolution. Following the identified self-assembly concept, conventional bulk activated carbon (AC) has been successfully transformed into CNTs through a detonation-induced cracking of AC and a real-time re-organization. [ABSTRACT FROM AUTHOR]

The article discusses a study which aims to explore the effect of lymphatic inhibition on joint and draining lymph node (LN) pathology on the course of arthritis progression in mice. The study used tumor necrosis factor (TNF)-transgenic mice as a model of chronic inflammatory arthritis. It found that lymphangiogenesis and lymphatic drainage are inversely related to the severity of joint lesions in the development of chronic arthritis.

Objective: To evaluate the therapeutic effect of treatment with a combination of the monoclonal antibodies to the vascular endothelial growth factor receptor (DC101) and the epidermal growth factor receptor (cetuximab) in an orthotopic nude mouse model of metastatic squamous cell carcinoma of the oral tongue (SCCOT). Design: In vivo study. Setting: A translational research laboratory at a comprehensive cancer center. Subjects: Male athymic nude mice aged 8 to 12 weeks. Intervention: To develop orthotopic nude mouse models of SCCOT, OSC-19 cells or luciferase (Luc)-expressing OSC-19-Luc and JMAR-Luc cells were injected into the tongues of nudemice. Animals were randomly divided into 4 groups: DC101 alone, cetuximab alone, DC101 plus cetuximab, or placebo, and all treatments were administered twice per week for 4 weeks. The in vivo antitumor activity was monitored noninvasively by bioluminescence imaging. Tumors were resected at necropsy, and immunohistochemical and immunofluorescent staining were performed. Main Outcome Measures: Tumor size, bioluminescence, animal survival, and percentage of animals with lymph node metastasis. Results: At the conclusion of the treatment period, the mean tumor volumes in the cetuximab alone and the DC101 plus cetuximab groups had decreased significantly compared with those that received the placebo control (68% [P=.002] and 84% [P<.001], respectively). Significant effects of the treatment were also observed in bioluminescence imaging. Mice treated with DC101 plus cetuximab also lived longer and had a lower incidence of neck lymph node metastases compared with the control group (P=.003). Conclusions: Treatment with DC101 plus cetuximab inhibited the growth of SCCOT and decreased the incidence of the neck lymph node metastases in vivo. These results suggest that this combination treatment may be an effective strategy against metastatic SCCOT and warrants further preclinical trials. [ABSTRACT FROM AUTHOR]

Myelosuppression damages the bone marrow (BM) vascular niche, but it is unclear how regeneration of bone marrow vessels contributes to engraftment of transplanted hematopoietic stem and progenitor cells (HSPC5) and restoration of hematopoiesis. We found that chemotherapy and sublethal irradiation induced minor regression of BM sinusoidal endothehal cells (SECs), while lethal irradiation induced severe regression of SECs and required BM transplantation (BMT) for regeneration. Within the BM, VEGFR2 expression specifically demarcated a continuous network of arterioles and SECs, with arterioles uniquely expressing Scal and SECs uniquely expressing VEGFR3. Conditional deletion of VEGFR2 in adult mice blocked regeneration of SECs in sublethally irradiated animals and prevented hematopoietic reconstitution. Similarly, inhibition of VEGFR2 signaling in lethally irradiated wild-type mice rescued with BMT severely impaired SEC reconstruction and prevented engraftment and reconstitution of HSPCs. Therefore, regeneration of SECs via VEGFR2 signaling is essential for engraftment of HSPCs and restoration of hematopoiesis. [ABSTRACT FROM AUTHOR]

The objective of this study was to evaluate the effects of combination therapy with photodynamic therapy (PDT) and a novel antiangiogenic regimen using monoclonal antibodies against both vascular endothelial growth factor receptors (VEGFR)-1 (MF1) and VEGFR-2 (DC101) on intracranial glioblastoma xenografts in nude mice. Nude mice bearing intracerebral U87 glioblastoma were treated with PDT and the antiangiogenic regimen (MF1 and DC101) either alone or in combination, while those left untreated served as tumor controls. Tumor volume and animal survival time were analyzed to evaluate the outcome of different treatment modalities. In addition, the immunohistochemical expression of VEGF in the brain adjacent to the tumor, von Willebrand factor (vWF), apoptotic, and proliferative markers in the tumor area were examined. PDT or MF1 + DC101 alone significantly reduced the tumor volume and prolonged the survival time of glioma-implanted animals. Combined therapy markedly reduced tumor volume and increased survival time with significantly better outcomes than both monotherapies. Both vWF and VEGF levels significantly increased after PDT while they both significantly decreased after antiangiogenic treatment, compared with no treatment. PDT plus antiangiogenic treatment led to significant decreases in both vWF and VEGF expression, compared with PDT alone. Either PDT or antiangiogenic treatment alone significantly increased tumor cell apoptosis compared with no treatment, while combination therapy resulted in further augmentation of apoptosis. Antiangiogenic treatment with or without PDT significantly decreased tumor cell proliferation, compared with either no treatment or PDT alone. In summary, we demonstrate both significant inhibition of tumor growth and extended survival of mice treated by the combination therapy with PDT and antiangiogenic agents, compared with each single treatment, suggesting that the combination therapy may be a promising strategy to improve clinical outcomes in glioblastoma. [ABSTRACT FROM AUTHOR]

Compelling experimental and clinical evidence suggests that epidermal growth factor receptor (EGFR) plays an important role in the pathogenesis of a variety of human cancers; thus, providing a strong rationale for the development of receptor antagonists as effective and specific therapeutic strategies for the treatment of EGFR-expressing cancers. Monoclonal antibodies (mAb), owing to their high specificity towards a given target, represent a unique class of novel cancer therapeutics. A number of anti-EGFR mAb are currently being developed in our clinic, including two that have been approved by the United States Food and Drug Administration for the treatment of refractory metastatic colorectal cancer (mCRC) and squamous cell carcinomas of the head and neck (SCCHN). Cetuximab (Er bitux, IMC-C225), an IgG1 mAb, has demonstr ated significant antitumor activity, both as a single agent and in combination with chemotherapeutics and radiation, in patients with refractory mCRC and SCCHN, respectively. Panitumumab (Vectibix), an IgG2 mAb, has been approved as a single agent for the treatment of patients with refractory mCRC. These mAb, via blocking ligand/receptor interactions, exert their biological activity via multiple mechanisms, including inhibition of cell cycle progression, potentiation of cell apoptosis, inhibition of DNA repair, inhibition of angiogenesis, tumor cell invasion and metastasis and, potentially, induction of immunological effector mechanisms. Anti-EGFR antibodies have demonstrated good safety profiles and potent anticancer activity in our clinic and may prove to be efficacious agents in the treatment of a variety of human malignancies. [ABSTRACT FROM AUTHOR]

The cellular and molecular mechanisms by which a tumour cell undergoes metastasis to a predetermined location are largely unknown. Here we demonstrate that bone marrow-derived haematopoietic progenitor cells that express vascular endothelial growth factor receptor 1 (VEGFR1; also known as Flt1) home to tumour-specific pre-metastatic sites and form cellular clusters before the arrival of tumour cells. Preventing VEGFR1 function using antibodies or by the removal of VEGFR1+ cells from the bone marrow of wild-type mice abrogates the formation of these pre-metastatic clusters and prevents tumour metastasis, whereas reconstitution with selected Id3 (inhibitor of differentiation 3)-competent VEGFR1+ cells establishes cluster formation and tumour metastasis in Id3 knockout mice. We also show that VEGFR1+ cells express VLA-4 (also known as integrin α4β1), and that tumour-specific growth factors upregulate fibronectin—a VLA-4 ligand—in resident fibroblasts, providing a permissive niche for incoming tumour cells. Conditioned media obtained from distinct tumour types with unique patterns of metastatic spread redirected fibronectin expression and cluster formation, thereby transforming the metastatic profile. These findings demonstrate a requirement for VEGFR1+ haematopoietic progenitors in the regulation of metastasis, and suggest that expression patterns of fibronectin and VEGFR1+VLA-4+ clusters dictate organ-specific tumour spread. [ABSTRACT FROM AUTHOR]

Mast cells accumulate in tissues undergoing angiogenesis during tumor growth, wound healing, and tissue repair. Mast cells can secrete angiogenic factors such as vascular endothelial growth factor (VEGF). Ionizing irradiation has also been shown to have angiogenic potential in malignant and nonmalignant diseases. We observed that low-dose irradiation fosters mast cell-dependent vascular regeneration in a limb ischemia model. Irradiation promoted VEGF production by mast cells in a matrix metalloproteinase-9 (MMP-9)-dependent manner. Irradiation, through MMP-9 up-regulated by VEGF in stromal and endothelial cells, induced the release of Kit-ligand (KitL). Irradiation-induced VEGF promoted migration of mast cells from the bone marrow to the ischemic site. Irradiation-mediated release of KitL and VEGF was impaired in MMP-9-deficient mice, resulting in a reduced number of tissue mast cells and delayed vessel formation in the ischemic limb. Irradiation-induced vasculogenesis was abrogated in mice deficient in mast cells (steel mutant, SI/SId mice) and in mice in which the VEGF pathway was blocked. Irradiation did not induce progenitor mobilization in SI/SId mice. We conclude that increased recruitment and activation of mast cells following irradiation alters the ischemic microenvironment and promotes vascular regeneration in an ischemia mode). These data show a novel mechanism of neovascularization and suggest that low-dose irradiation may be used for therapeutic angiogenesis to augment vasculogenesis in ischemic tissues. [ABSTRACT FROM AUTHOR]

Acrylamide (ACR) is known to produce central–peripheral distal axonopathy, which is characterized by distal swellings and secondary degeneration both in experimental animals and human. Ultrastructurally, excessive accumulation of neurofilaments (NFs) in the distal swollen axon is a major pathological hallmark. However, the mechanisms of ACR axonopathy remain unknown. Twenty seven male Wistar rats were randomly divided into three groups. Lower and higher ACR groups were received 20 and 40 mg/kg ACR by i.p. injection respectively. The control group received physiological saline. All rats were sacrificed after 8 weeks of treatment and their cerebrums were dissected, homogenized and used for the determination of the NF proteins. In general, the levels of light NF (NF-L) and medium NF (NF-M) subunits increased consistently in the supernatant, whereas they decreased consistently in the pellet from rats treated with ACR. Compared to that of the control group, the levels of NF-L increased respectively by 104% and 45% (P<0.01) in the supernatant and decreased by 16% and 11% (P<0.01) in the pellet of rat cerebrums in lower and higher groups. The enhancement of NF-M was 76% and 147% (P<0.05, P<0.01) in supernatant, and the reduction was 26% and 36% (P<0.01) in pellet in lower and higher group respectively. The heavy NF (NF-H) level changed slightly. The present results suggested that the change of NF-L and NF-M levels in cerebrum might be relevant to the mechanisms of the neurofilamentous axonopathies induced by ACR. [ABSTRACT FROM AUTHOR]

One of the major obstacles in the development of bispecific antibodies (BsAb) has been the difficulty of producing the materials in sufficient quality and quantity by traditional technologies, such as the hybrid hybridoma and chemical conjugation methods. In contrast to the rapid and significant progress in the development of recombinant BsAb fragments (such as diabody and tandem single chain Fv), the successful design and production of full length IgG-like BsAb has been limited. Compared to smaller fragments, IgG-like BsAb have long serum half-life and are capable of supporting secondary immune functions, such as antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. The development of IgG-like BsAb as therapeutic agents will depend heavily on our research progress in the design of recombinant BsAb constructs (or formats) and production efficiency. This review will focus on recent advances in various recombinant approaches to the engineering and production of IgG-like BsAb. [ABSTRACT FROM AUTHOR]

Exposure chronically to n-hexane produces peripheral–central axonopathy mediated by 2,5-hexanedione (HD). Previous studies have demonstrated decreases in neurofilament (NF) contents of peripheral and central nervous regions from rats intoxicated with HD, and recent analysis has demonstrated that axonal atrophy, instead of NF-filled swellings, is a specific component of morphologic alterations. To deeply investigate the alterations of cytoskeletal proteins in HD peripheral neuropathy, the relative levels of NF-L, NF-M, NF-H, a-tubulin, ß-tubulin and ß-actin of rat sciatic–tibial nerves were determined by SDS-PAGE and immunoblotting. HD was administrated to Wistar rats by intraperitoneal injection at dosage of 200 or 400 mg/kg/day (five-times per week). Rats were sacrificed after 6 weeks of treatment, and sciatic–tibial nerves were dissected, homogenized, and used for the determination of cytoskeletal proteins. Except for supernatant NF-L that could not be assayed, the results showed HD intoxication was associated with significant decreases in NF subunits in both of the supernatant and the pellet fractions of sciatic–tibial nerve homogenates (P<0.01), and obvious reductions in a-tubulin, ß-tubulin and ß-actin only in the supernatant (P<0.05 or P<0.01). Among these alterations, the falls in the levels of NF subunits tended to be greater compared to those of the other cytoskeletal proteins in all HD-exposed groups, and the trend for decrements in NF-M was greater than those in the other NF subunits. Thus, HD intoxication was associated with significant declines in cytoskeletal protein contents in rat sciatic–tibial nerves, and the decreases might be related to the involvement of the peripheral axonopathy induced by HD. [ABSTRACT FROM AUTHOR]

Recombinant protein production in plants such as corn is a promising means to generate high product yields at low comparable production cost. The anti-EGFR monoclonal antibody C225, cetuximab, is a well-characterized receptor antagonist antibody recently approved for the treatment of refractory colorectal cancer. We initiated a study to test and compare the functional activity of glycosylated and aglycosylated C225 produced in stable transgenic corn seed. Both corn antibodies were shown to be functionally indistinguishable from mammalian-derived C225 in demonstrating high-affinity binding to the EGF receptor, blocking of ligand-dependent signaling, and inhibiting cell proliferation. In addition, consistent with cetuximab, both corn antibodies possessed strong anti-tumor activity in vivo. Acute dose primate pharmacokinetic studies, however, revealed a marked increase in clearance for the glycosylated corn antibody, while the aglycosylated antibody possessed in vivo kinetics similar to cetuximab. This experimentation established that corn-derived receptor blocking monoclonal antibodies possess comparable efficacy to mammalian cell culture-derived antibody, and offer a cost effective alternative to large-scale mammalian cell culture production. [ABSTRACT FROM AUTHOR]

In this report we utilize a novel antagonist antibody to the human VEGFR-3 to elucidate the role of this receptor in in vitro tubular morphogenesis of bovine and human endothelial cells (EC cells) induced by VEGF-C. The antibody hF4-3C5 was obtained by panning a human phage display library on soluble human VEGFR-3. The binding affinity constant of hF4-3C5 significantly exceeds that of the interaction of VEGFR-3 with VEGF-C. hF4-3C5 strongly inhibits the binding of soluble VEGFR-3 to immobilized VEGF-C and abolishes the VEGF-Cmediated mitogenic response of cells that expresses a chimeric human VEGFR-3-cFMS receptor. In fluorescence experiments, hF4-3C5 reactivity is observed with human lymphatic endothelial cells (LECs) and human umbilical vein endothelial cells (HUVECs). Binding of hF4-3C5 shows that about half of bovine aortic endothelial (BAE) cells express VEGFR-3 and cells in this subpopulation are primarily responsible for the chemotactic response to the mature form of VEGF-C (VEGF-CΔNΔC). This response was strongly inhibited by the addition of hF4-3C5. In vitro tube formation by BAE cells induced by VEGF-CΔNΔC was reduced by greater than 60% by hF4-3C5 whereas the response to VEGF165 was unaffected. Addition of hF4-3C5 together with an antagonist antibody to VEGFR-2 completely abolished the response to VEGF-CΔNΔC. Similar results were obtained with HUVECs. Together, these findings point to a role for VEGFR-3 in vascular tubular morphogenesis and highlight the utility of hF4-3C5 as a tool for the investigation of the biology of VEGFR-3. [ABSTRACT FROM AUTHOR]

The detonation of carbon- or nitrogen-containing explosives not only produces powerful shock waves but also provides elemental building blocks and a unique high-pressure and high-temperature physical environment for the construction of various nanostructures. This review highlights the situation and key progresses in the detonation approach towards diamond nanoparticles, graphitic carbon nanotubes, fullerene molecules, and gallium nitride nanocrystals. Further extension of the peaceful-use detonation applications and rational reactor design are also proposed. [ABSTRACT FROM AUTHOR]

Examines the role of antiangiogenic agents for blocking the effects of tumor-derived angiogenic factors. Inhibition of both paracrine and autocrine signalling pathways; Importance of two pathways for inducing long-term remission of xenotransplanted human leukemia.

The effects of SO2, V2O5 loading and reaction temperature on the activity of activated carbon supported vanadium oxide catalyst have been studied for the reduction of NO with NH3 at low temperatures (150—250°C). It is found that SO2 significantly promotes the catalyst activity. Both V2O5 loading and reaction temperature are vital to the promoting effect of SO2. The catalysts with V2O5 loadings of 1—5 weight percent have a positive effect on the promotion of SO2, while the catalysts with V2O5 loadings of above 7 weight percent have not such an effect or show a negative effect. At lower temperatures (<180°C) SO2 poisons the catalyst but at higher temperatures promotes it. The reason of the SO2 promotion was also discussed; it may results from the formation of SO4 2− on the catalyst surface, which increases the surface acidity and hence the catalytic activity. [ABSTRACT FROM AUTHOR]

The article presents a study which showed that the granulocyte colony-stimulating factor, a growth factor used for stem and progenitor cell mobilization in malignant and nonmalignant disease, has angiogenic potential. Principal findings are revealed. Conclusions and significance of the study are discussed.

Replying to: M. R. Dawson et al. 461, 10.1038/nature08254 (2009)Commenting on ref. 1, Dawson et al. claim that metastasis formation is independent of VEGFR1 activity, contradicting work by us and many others, including the original description of flt1TK-/- (VEGFR1-TK-/-) mice in the metastatic setting. Contrasting the findings by Dawson et al., here we show that VEGFR1 knockdown in myelomonocytic cells eradicates micro- and macrometastases in a non-amputation/resection tumour model. [ABSTRACT FROM AUTHOR]

A novel in situ method based on a liquid membrane templated self-assembly process is employed to modify carbon tube-in-tube nanostructures (TTCNTs) with Fe2O3 nanoparticles. The as-obtained Fe2O3 modified TTCNTs (Fe2O3/TTCNTs) nanocomposites are well constructed and the Fe2O3 nanoparticles are well dispersed and decorated on the outer, inner and intramolecular surfaces of TTCNTs. In addition, the Fe2O3/TTCNTs nanocomposites are employed as catalysts for selective catalytic reduction (SCR) of NO with NH3 and show high SCR catalytic activity, indicating that the novel multiple intramolecular channels and unique surface chemistry of the TTCNTs should play an important role in improving the properties of TTCNTs. [ABSTRACT FROM AUTHOR]

The relative content of carboxyl and hydroxyl groups on carbon nanotubes (CNTs) was tuned through a controlled reduction process. It was found that the CNTs decorated by varying ratio of carboxyl and hydroxyl groups can obviously enhance the catalytic activity of supported vanadium oxide catalysts for selective catalytic reduction (SCR) of NO with NH3. The improvement effects induced by carboxyl and hydroxyl groups depend significantly on the reacting feedstock with and without SO2 and H2O. In the absence of SO2 and H2O, hydroxyl-modified CNT supported vanadium oxide (Vx+yO2-z (x ... 4)/CNTs-OH) shows more significant improvement on SCR activity, while more obviously promoting effect was observed over carboxyl-modified CNT supported vanadium oxide (Vx+yO2-z (x ... 5)/CNTs-COOH) catalyst in the presence of SO2. The variation in oxidation states of active vanadium species (V5+, V4+ and V3+) originated from the electronic interactions between carboxyl and hydroxyl modified CNTs and vanadium precursors are indicated to be the main reason for the very different SCR performances over the two Vx+yO2-z/CNTs catalysts. Low valence V4+ and V3+ species show much higher SCR activity in the absence of SO2 and H2O, while the high valence V5+ species are very beneficial to NO reduction in the presence of SO2. The V5+ species have an excellent catalytic ability of oxidizing SO2 to SO3, leading to the in situ formation of ammonium sulfate, and are capable of catalyzing the reaction between the sulfate salts and NO. Furthermore, both of the Vx+yO2-z/CNTs catalysts are very stable for SCR of NO even in the presence of SO2 and H2O. These findings give some insight into the mechanisms behind the SCR reaction over CNT supported vanadium oxides, which would be beneficial to the design and synthesis of more efficient and much stable SCR catalysts. [ABSTRACT FROM AUTHOR]

Both laboratory and early clinical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially significant application in cancer therapy. The clinical development of BsAb as therapeutics has been hampered, however, by the difficulty in preparing the materials in sufficient quantity and quality by traditional methods. In recent years, a variety of recombinant methods has been developed for efficient production of BsAb, both as antibody fragments and as full-length IgG-like molecules. Here we describe a novel recombinant approach for the production of an Fc domain-containing, IgG-like tetravalent BsAb, with two antigen-binding sites to each of its target antigens, by genetically fusing a single variable domain antibody to the N terminus of the light chain of a functional IgG antibody of different specificity. A model BsAb was constructed using a single variable domain antibody to mouse platelet-derived growth factor receptor a and a conventional IgG antibody to mouse vascular endothelial growth factor receptor 2. The BsAb was expressed in mammalian cells and purified to homogeneity by one-step protein A affinity chromatography. Furthermore, the BsAb retains the antigen binding specificity and the receptor neutralizing activity of both of its parent antibodies. This design and expression of Fc domain-containing, IgG-like BsAb should be applicable to the construction of similar BsAb from antibodies recognizing any pair of antigens. [ABSTRACT FROM AUTHOR]